Top Markets
Coin of the day
Relmada Therapeutics, Inc. Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD
Rangering i aksjer #13829
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company... Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Aksjekurs
$4.36
Markedsverdi
$457.32M
Endring (1 dag)
0.69%
Endring (1 år)
289.29%
Land
US
Handel Relmada Therapeutics, Inc. (RLMD)

Kategori

Utbyttehistorikk for Relmada Therapeutics, Inc. (RLMD)
Relmada Therapeutics, Inc. (aksjesymbol: RLMD) har gitt totalt 0 utbyttebetalinger.
Summen av alle utbytter (justert for aksjesplitt): 0.00
Utbytteavkastning (TTM): 0
Utbyttebetalinger for Relmada Therapeutics, Inc. (RLMD) fra 2026 til 2026
Årlige utbyttebetalinger
År Utbytte (justert for aksjesplitt) Endre
Ikke nok data for de angitte datoene.
Liste over alle utbyttebetalinger
År Utbytte Endre
Ikke nok data for de angitte datoene.
Utbyttebetalinger for lignende selskaper eller konkurrenter
Selskap Antall utbyttebetalinger Land
0.00%
US
0.00%
NL
64.00%
AU
0.00%
US
0.00%
CH